Hyaluronic acid-modified cationic nanoparticles overcome enzyme CYP1B1-mediated breast cancer multidrug resistance

被引：18
作者：
Zhang, Jun [1 ]
Song, Jia [1 ]
Liang, Xiao [1 ]
Yin, Yunzhi [1 ]
Zuo, Tiantian [1 ]
Chen, Daijie [1 ]
Shen, Qi [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China
来源：
NANOMEDICINE | 2019年 / 14卷 / 04期
关键词：
alpha-napthtoflavone; breast cancer; CD44; CYP1B1; DTX; hyaluronic acid; lysosome escape; multidrug resistance; nanoparticles; polyethyleneimine; MESOPOROUS SILICA; ANTICANCER DRUGS; DELIVERY; DOCETAXEL; MICELLES; CYP1B1; CYTOCHROME-P450; PACLITAXEL; CELLS; FORMULATIONS;
D O I：
10.2217/nnm-2018-0244
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: Enzyme CYP1B1 (CYP1B1) is usually overexpressed in multidrug resistance (MDR) breast cancer cells, which could metabolically inactivate docetaxel (DTX). Materials & methods: The cationic core-shell nanoparticles (hyaluronic acid/polyethyleneimine nanoparticles[HA/PEI NPs]) modified with hyaluronic acid (HA) were developed and coloaded with DTX and alpha-napthtoflavone (ANF, a CYP1B1 inhibitor) to overcome MDR in breast cancer induced by CYP1B1. Physicochemical characterization, MDR reversing effect in vitro and pharmacokinetics in vivo of HA/PEI NPs were evaluated. Results: The HA/PEI NPs exhibited spherical morphology with size of (193.6 +/- 3.1) nm. The HA/PEI NPs could reverse MDR effectively by downregulating the expression of CYP1B1. The HA/PEI NPs improved the bioavailability of DTX. Conclusion:The HA/PEI NPs might be a promising strategy to overcome CYP1B1-mediated breast cancer MDR. [GRAPHICS]
引用
收藏
页码：447 / 464
页数：18
相关论文
共 50 条
  • [21] Upregulation of CYP1B1 by hypoxia is mediated by ERα activation in breast cancer cells
    Min, Jin Young
    Lee, Gi Ho
    Khanal, Tilak
    Jin, Sun Woo
    Lee, Sang-Yeop
    Kim, Hyung Gyun
    Hyon, Ju-Yong
    Chung, Young-Ho
    Ha, Sang Keun
    Han, Eun Hee
    Jeong, Hye Gwang
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (06): : 2798 - 2816
  • [22] Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery
    Zhang, Xin
    Pan, Jiayi
    Yao, Momei
    Mendes, Livia Palmerston
    Sarisozen, Can
    Mao, Shirui
    Torchilin, Vladimir P.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2020, 154 : 43 - 49
  • [23] Redefine the role of D-α-Tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein, multidrug resistance protein 1, and breast cancer resistance protein mediated cancer multidrug resistance
    Chen, Jing-Yi
    Sung, Chieh-Ju
    Chen, Ssu-Chi
    Hsiang, Yi-Ping
    Hsu, Yung-Chia
    Teng, Yu-Ning
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 190
  • [24] Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy
    Li, Lin
    Di, Xingsheng
    Wu, Mingrui
    Sun, Zhisu
    Zhong, Lu
    Wang, Yongjun
    Fu, Qiang
    Kan, Qiming
    Sun, Jin
    He, Zhonggui
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2017, 13 (03) : 987 - 998
  • [25] Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer
    Yang, Xiaoxia
    Shang, Pengfei
    Ji, Jianbo
    Malichewe, Christina
    Yao, Zhiyin
    Liao, Jing
    Du, Dandan
    Sun, Chao
    Wang, Lei
    Tang, Ya-jie
    Guo, Xiuli
    MOLECULAR PHARMACEUTICS, 2022, 19 (01) : 2 - 17
  • [26] Targeting HSP90AA1 to overcome multiple drug resistance in breast cancer using magnetic nanoparticles loaded with salicylic acid
    Chen, Ou
    Fu, Linlin
    Wang, Yu
    Li, Jinggui
    Liu, Jun
    Wen, Yanqing
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 298
  • [27] Cationic anticancer peptide L-K6-modified and doxorubicin-loaded mesoporous silica nanoparticles reverse multidrug resistance of breast cancer
    Sun, Haiting
    Dong, Shaodan
    Kong, Lingying
    Wang, Rongchun
    Zhao, Jiaqi
    Guan, Yue
    Wang, Che
    Shang, Dejing
    ARABIAN JOURNAL OF CHEMISTRY, 2024, 17 (05)
  • [28] Folic acid-modified disulfiram/Zn-IRMOF3 nanoparticles for oral cancer therapy by inhibiting ALDH1A1+cancer stem cells
    Cui, Jiasen
    Li, Weitao
    Bu, Wenhuan
    Liu, Jinhui
    Chen, Xi
    Li, Xuewen
    Liu, Chunran
    Meng, Lin
    Chen, Mingli
    Sun, Hongchen
    Wang, Jianhua
    BIOMATERIALS ADVANCES, 2022, 139
  • [29] B7-H3-mediated deubiquitination stabilizing CYP1B1 expression promotes chemotherapy resistance in colorectal cancer
    Liu, Huan
    Li, Guifang
    Shen, Chenjie
    Qi, Xiaowei
    Liu, Yankui
    Hua, Dong
    Mao, Yong
    Zhang, Ting
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2025, 1871 (05):
  • [30] FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells
    Zhang, Meng
    Zeng, Xiaoqi
    She, Meiling
    Dong, Xingduo
    Chen, Jun
    Xiong, Qingquan
    Qiu, Guobin
    Yang, Shuyi
    Li, Xiangqi
    Ren, Guanghui
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2024, 57
12345